meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
atezolizumab plus pemetrexed and platin
cemiplimab
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus SoC
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab and pemetrexed plus platin
pembrolizumab plus SoC
sintilimab based treatment
sintillimab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
nivolumab plus ipilimumab plus SoC
pembrolizumab plus ipilimumab
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs nucleoside analogues (pyrimidine/purine)
vs gemcitabine
vs taxanes
vs paclitaxel
vs nab-paclitaxel
vs vinca alkaloids
vs vinorelbine
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs gemcitabine plus platin
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs pemetrexed plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
vs immune chekpoint inhibitors
vs anti-PD-(L)1
vs atezolizumab based treatment
vs atezolizumab plus carboplatin plus nab-paclitaxel
vs pembrolizumab based treatment
vs pembrolizumab alone
vs pembrolizumab plus placebo
vs pembrolizumab plus SoC
vs non active control
vs no additional treatment
vs placebo
vs placebo plus BSC
vs VEGF(R) inhibitor
vs bevacizumab based treatment
vs bevacizumab plus carboplatin and paclitaxel
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
atezolizumab plus pemetrexed and platin
title
pemetrexed plus platin
title
IMpower-132 (WT), 0 NCT02657434 non squamous - mNSCLC - L1 - Wild Type (WT) 292/286
Pathology:
non squamous - mNSCLC - L1 - Wild Type (WT);
non squamous - mNSCLC - L1 - Wild Type (WT)
IMpower-132 (WT), 0
atezolizumab plus pemetrexed and platin
1
T1
pemetrexed plus platin
0
T0